Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
transmid
- Development stage
- Phase 3
- Lead developer
- Xenova
- Modality
- Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intratumoral
01
Overview
TransMID is an investigational **transferrin-diphtheria toxin conjugate** developed for recurrent or progressive **glioblastoma multiforme**. It consists of human transferrin linked to **CRM107**, a mutated form of diphtheria toxin, and is administered directly into tumor tissue or the interstitium to exploit overexpression of the **transferrin receptor** on malignant glioma cells. After receptor-mediated uptake, the diphtheria toxin moiety inhibits protein synthesis and causes tumor cell death, making TransMID a targeted local antineoplastic biologic/fusion toxin therapy. Publicly verifiable sources include Phase III clinical trial records sponsored by Xenova and the National Institute of Neurological Disorders and Stroke for non-resectable recurrent glioblastoma multiforme.
- Brand names
- TransMID
- Other names
- transmidtransferrin-CRM107 conjugatetransferrin-CRM-107 conjugatetransferrin-CRM 107 conjugateTf-CRM107Tf-CRM-107Tf-CRM 107
02
Targets
EEF2 (Eukaryotic elongation factor 2)TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on transmid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on transmid.